JP2022553292A5 - - Google Patents
Info
- Publication number
- JP2022553292A5 JP2022553292A5 JP2022523383A JP2022523383A JP2022553292A5 JP 2022553292 A5 JP2022553292 A5 JP 2022553292A5 JP 2022523383 A JP2022523383 A JP 2022523383A JP 2022523383 A JP2022523383 A JP 2022523383A JP 2022553292 A5 JP2022553292 A5 JP 2022553292A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962923644P | 2019-10-21 | 2019-10-21 | |
| US62/923,644 | 2019-10-21 | ||
| PCT/US2020/056723 WO2021081133A1 (en) | 2019-10-21 | 2020-10-21 | Engineered natural killer cells and methods for using the same in immunotherapy and autophagy inhibition techniques |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022553292A JP2022553292A (ja) | 2022-12-22 |
| JP2022553292A5 true JP2022553292A5 (https=) | 2024-01-04 |
| JPWO2021081133A5 JPWO2021081133A5 (https=) | 2024-01-04 |
Family
ID=75620220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022523383A Pending JP2022553292A (ja) | 2019-10-21 | 2020-10-21 | 操作されたナチュラルキラー細胞、ならびに免疫療法およびオートファジー阻害技法においてそれを使用するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220362299A1 (https=) |
| EP (1) | EP4048292A4 (https=) |
| JP (1) | JP2022553292A (https=) |
| AU (1) | AU2020371628A1 (https=) |
| CA (1) | CA3155246A1 (https=) |
| WO (1) | WO2021081133A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| CN113621073A (zh) * | 2021-07-14 | 2021-11-09 | 上海易慕峰生物科技有限公司 | 一种新型嵌合受体组合物、重组载体、细胞及其应用 |
| CN120459135B (zh) * | 2025-07-16 | 2025-10-10 | 深圳市中佳生物医疗科技有限公司 | Cd73+nk细胞在制备预防或治疗帕金森的药物中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2948544A4 (en) * | 2013-01-28 | 2016-08-03 | St Jude Childrens Res Hospital | CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES |
| GB201403972D0 (en) * | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
| EP3218407A1 (en) * | 2014-11-11 | 2017-09-20 | Medimmune Limited | Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof |
| MY189836A (en) * | 2014-11-21 | 2022-03-11 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| WO2017172981A2 (en) | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| WO2017186121A1 (zh) * | 2016-04-26 | 2017-11-02 | 科济生物医药（上海）有限公司 | 一种改善免疫应答细胞功能的方法 |
| US20180100016A1 (en) * | 2016-12-22 | 2018-04-12 | Xiaotong Song | Use of car-modified human natural killer cells to treat cancer |
| AU2018269194B2 (en) * | 2017-05-15 | 2025-05-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bicistronic chimeric antigen receptors and their uses |
-
2020
- 2020-10-21 JP JP2022523383A patent/JP2022553292A/ja active Pending
- 2020-10-21 AU AU2020371628A patent/AU2020371628A1/en active Pending
- 2020-10-21 EP EP20879537.7A patent/EP4048292A4/en active Pending
- 2020-10-21 WO PCT/US2020/056723 patent/WO2021081133A1/en not_active Ceased
- 2020-10-21 US US17/770,585 patent/US20220362299A1/en active Pending
- 2020-10-21 CA CA3155246A patent/CA3155246A1/en active Pending